I think you will find analysts starting to cover VTGN at some point, it is too big of an asset. My thinking is after the NIH release results of Phase 2a analysts will catch up with data.
Normally this type of potential blockbuster would already be on analysts radar. The low PPS and the fact that VTGN was so low on cash before might have something to do with the current lack of analysts. Most bio techs working on a block buster drug have a couple hundred million dollars in the bank.
In addition to depression, which is the blockbuster, the NIH was originally interested in AV 101 for pain. Just look at the opiod crisis.
Peer reviews also are positive for Hodgkinson's and Parkinson's and they have a separate asset in the stem cell area.
Try to find me another bio working on a billion dollar drug with no negatives trading at 1.5.. This has 10 to 20 time potential in a small 12 to 24 month window.
I can virtually guarantee you every major pharma that has an interest in depression or a potential blockbuster has VTGN on their follow list and will be keen to get a look at data when it starts flowing.
It is not a surprise that Sage market cap went up 2 billion dollars on a positive phase 2 trial. FDA has allowed VTGN to improve formulation mid trial and granted them fast track status.
The people in VTGN are super professional.
News 
Market Data 
Discover 
